Landos Biopharma, Inc. (NASDAQ: LABP) had its price target lowered by analysts at SVB Leerink LLC from $16.00 to $3.00. They now have a "market perform" rating on the stock.
Landos Biopharma, Inc. (LABP)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
LABP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LABP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LABP alerts
High impacting Landos Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LABP
News
- LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABPBusiness Wire
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates LABP, WRK, TGAN, KAMNAccesswire
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPPR Newswire
- Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]Yahoo! Finance
- Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 ResultsGlobeNewswire
LABP
Sec Filings
- 3/26/24 - Form DEFA14A
- 3/25/24 - Form DEFA14A
- 3/21/24 - Form S-8
- LABP's page on the SEC website